Tech Company Financing Transactions
Cayuga Biotech Funding Round
Wharton Alumni Angels, Defense Health Agency and Gopher Angels joined a $8 million Seed venture round for Cayuga Biotech. This venture round was announced on 12/11/2025.
Transaction Overview
Company Name
Announced On
12/11/2025
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Seed
Investors
Proceeds Purpose
This funding will help advance the Phase 1 clinical trial for CAY001, a first-in-class, synthetic polyphosphate-silica nanoparticle (polyP-SNP) complex, to generate human proof-of concept data in 2026.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Eighth Avenue, Front 3 1596
New York, NY 10018
USA
New York, NY 10018
USA
Phone
Undisclosed
Website
Email Address
Overview
Cayuga Biotech, a clinical-stage biopharmaceutical company, is developing novel therapies to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding. Cayuga's pipeline includes clinical-stage CAY001 (polyP-SNP complex), in development for acute major hemorrhage, CAY002, a discovery-stage program for inherited bleeding disorders and a portfolio of early-stage programs across the healing continuum.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrea Ashford-Hicks
Browse more venture capital transactions:
Prev: 12/11/2025: Skydo venture capital transaction
Next: 12/11/2025: Allegria Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs